



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61L 15/38, 15/46</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/08726</b> <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/DK98/00352 <b>(22) International Filing Date:</b> 14 August 1998 (14.08.98) <b>(30) Priority Data:</b> 0937/97 14 August 1997 (14.08.97) DK <b>(71) Applicant:</b> NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). <b>(72) Inventors:</b> KIRK, Ole; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). JOHANSEN, Charlotte; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK). HANSEN, Tomas, Tage; Novo Nordisk a/s, Novo Allé, DK-2880 Bagsværd (DK).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> REDUCTION OF MALODOUR  <b>(57) Abstract</b>  The present invention relates to the use of a haloperoxidase in combination with a hydrogen peroxide source for reducing the malodour emanating from soiled hygiene products. The invention also relates to hygiene products with reduced malodour in soiled state.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**Titl : Reduction of malodour**

**FIELD OF THE INVENTION**

The present invention relates to the use of a haloperoxidase in combination with a hydrogen peroxide source for reducing the malodour emanating from soiled hygiene products. The invention also relates to hygiene products with reduced malodour in soiled state.

**10 BACKGROUND OF THE INVENTION**

It is well established that malodour may be caused by a number of compounds including Volatile Sulphuric compounds (VSC), nitrogen containing compounds and short fatty acids.

A source of nitrogen containing compounds, such as ammonia, is urine, faeces and blood giving a bad smell known by most people from either soiled diapers or other hygiene products, such as adult incontinence products, training pants, feminine napkins, tampons and the like.

The bad smell coming from diapers and the like is at least partly a consequence of growth of bacteria, especially *Escherichia coli*, *Enterococcus spp.* and *Proteus spp.* present on the skin in the perineum (the region between the anus and the external sexual organs). All strains of *Proteus spp.* form the enzyme urease during their metabolism. Urease has the ability to rapidly break down urea (constituting about 2% of human urine) into ammonia causing an unpleasant odour.

Removal or reduction of malodour in hygiene products

A number of odour controlling agent and systems have been described in the literature. For instance, carbon is e.g. in the form of activated carbon well-known for its ability to adsorb odoriferous molecules.

US patent no. 5,593,398 discloses protective underwear with malodorous flatus filter comprising activated carbon as the malodour controlling agent

Zeolitic materials have been shown to be effective against

malodour associated with body fluids.

JP patent application no. 02068117 relates to deodorising means e.g. for diapers containing zeolite, copper and activated charcoal.

5 US patent no. 3,903,259 concerns a method of deodorising diapers and human excreta comprising applying to the diapers or the excreta a chemical composition which in its simplest form consists of an acidic material, an antibiotic material, and a solvent. The impregnating composition may also contain a  
10 chelating agent and a wetting agent. The treatment of diapers results in a marked decrease in offensive odours from excreta, thus making the changing of sorted diapers less unpleasant.

US patent no. 3,935,862 discloses a disposable diaper comprising means for inhibiting ammonia formation therein  
15 including an aminopolycarboxylic acid compound in an amount of at least 0.001 g per square inch.

US patent no. 4,385,632 concerns a germicidal absorbent body for collecting blood, faeces and urine which contains a water-soluble copper salt which impedes bacterial growth, prevents the  
20 breaking down of urea into ammonia and complex-binds ammonia so as to prevent the occurrence of unpleasant odour.

#### SUMMARY OF THE INVENTION

It is the object of the present invention to provide a  
25 hygiene product which in soiled state has a reduced malodour.

In the first aspect the invention relates to the use of a haloperoxidase in combination with a hydrogen peroxide source for reducing the malodour in hygiene products.

In the second aspect the invention relates to hygiene  
30 products having a haloperoxidase and a hydrogen peroxide source incorporated e.g. in the absorbing material. Specifically contemplated hygiene product include diapers, adult incontinence products, training pants, feminine napkins, tampons and the like.

#### 35 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a response surface plot for the

antibacterial activity in artificial urine of a *Curvularia* haloperoxidase (rHP) against a mixed culture of *E. faecalis*, *E. coli* and *P. mirabilis* adhering to CTMP.

Figure 2 shows a response surface plot for the  
5 antibacterial activity of rCIP and KI ( $H_2O_2 = 0.5$  mM) against *Proteus mirabilis* (planktonic cells).

Figure 3 shows the bactericidal activity of rCIP/KI, rCIP/NaSCN and haloperoxidase (rHP) against *P. mirabilis* in artificial urine. Cells were either suspended (planktonic) in  
10 artificial urine or adhering to CTMP.

#### DETAILED DESCRIPTION OF THE INVENTION

It is the object of the present invention to provide a hygiene product which in soiled state has a reduced malodour.

15 The term "hygiene product" covers any product suitable for adsorbing or collecting urine, faeces, blood and the like. Examples of hygiene products contemplated are diapers, adult incontinence products, training pants, feminine napkins and tampons.

20 Hygiene products typically comprise an absorbing material for collecting body fluids and the like. Polyacrylate superabsorbers are often used today. These superabsorbers are capable of absorbing many times their own weight in liquid, such as urine, making it possible to provide thin and less bulky hygiene products capable of holding an increasing amount of liquid before  
25 leaking the fluid. These increased amounts of liquid in the hygiene product increase the malodour problem making a solution of the problem more insistent.

In the context of the present invention the term "malodour"  
30 means an unpleasant bad smell caused by e.g. nitrogen containing compounds such as ammonia.

The term "absorbing material" covers all kinds of materials capable of holding back liquids.

The inventors have found that haloperoxidases in combination  
35 with a hydrogen peroxide source can be used for reducing the malodour of soiled hygiene products.

The term "reducing the malodour" or "reduced malodour" means that the malodour determined by a test panel is assessed to be less pronounced in comparison to a corresponding blind sample.

The bad smell emanating from soiled hygiene products is typically a consequence of nitrogen containing compounds. Urine, faeces, blood and the like are degraded by enzymes produced by bacteria living on the skin covered by the hygiene product. For instance, the enzyme urease, capable of converting urine into ammonia, is produced by bacteria from *Proteus spp.* living on the skin in the perineum (the region between the anus and the external sexual organs).

In the first aspect the invention relates to the use of a haloperoxidase in combination with hydrogen peroxide source for reducing the malodour of hygiene products.


As will be illustrated in the Examples below a haloperoxidase in combination with a hydrogen peroxide source can be used for significantly reducing the malodour arising in soiled hygiene products by inhibition of the urease activity or by killing or at least inhibiting the growth of micro-organisms, such as bacteria, producing compounds, in particular enzymes, responsible for the degradation of urine and the like into bad smelling compounds.

When the haloperoxidase comes in contact with halide ions (especially  $\text{Cl}^-$ ) in the urine, the halide ions are oxidised into hypohalous acid (e.g. hypochlorite (i.e.  $\text{ClO}^-$ )) (and probably also other oxidative compounds) which inhibits the activity of urease or is capable of killing or at least inhibiting the growth of microbial cells, such as bacteria cell.

The haloperoxidase may be incorporated into the absorbing material of the hygiene product. A person skilled in the art of hygiene products knows where and how to incorporate the haloperoxidase and the hydrogen peroxide source. The only mandatory criteria is that the haloperoxidase and the hydrogen peroxide are incorporated so that it comes in contact with and can react with halide ions present in e.g. the urine.

### Haloperoxidases

Haloperoxidases form a class of enzymes which are able to oxidize halides (Cl-, Br-, I-) in the presence of hydrogen peroxide or a hydrogen peroxide generating system to the corresponding hypohalous acids according to:



If a convenient nucleophilic acceptor is present, a reaction will occur with HOX and a halogenated compound will be formed.

There are three types of haloperoxidases, classified according to their specificity for halide ions: Chloroperoxidases (E.C. 1.11.1.10) which catalyse the chlorination, bromination and ionidation of compounds; Bromoperoxidases which show specificity for bromide and iodide ions; and iodoperoxidases (E.C. 1.11.1.8) which solely catalyze the oxidation of iodide ions.

Haloperoxidases have been isolated from various organisms: mammals, marine animals, plants, algae, a lichen, fungi and bacteria (for reference see Biochimica et Biophysica Acta 1161, 1993, pp. 249-256). It is generally accepted that haloperoxidases are the enzymes responsible for the formation of halogenated compounds in nature, although other enzymes may be involved.

Haloperoxidases have been isolated from many different fungi, in particular from the fungus group dematiaceous hyphomycetes, such as *Caldariomyces*, e.g., *C. fumago*, *Alternaria*, *Curvularia*, e.g., *C. verruculosa* and *C. inaequalis*, *Drechslera*, *Ulocladium* and *Botrytis* (see US Patent No. 4,937,192).

According to the present invention a haloperoxidase obtainable from *Curvularia*, in particular *C. verruculosa* is preferred such as *C. verruculosa* CBS 147.63 or *C. verruculosa* CBS 444.70. *Curvularia* haloperoxidase and recombinant production hereof is described in WO 97/04102.

Haloperoxidases have also been isolated from bacteria such as *Pseudomonas*, e.g., *P. pyrrocinia* (for reference see The Journal of Biological Chemistry 263, 1988, pp. 13725-13732) and *Streptomyces*, e.g., *S. aureofaciens* (for reference see Structural

Biology 1, 1994, pp. 532-537).

Bromide peroxidase has been isolated from algae (see US Patent No. 4,937,192).

In use, the concentration of the haloperoxidase may be varied  
5 in order to achieve the desired effect within the desired time  
frame. However, according to the invention the haloperoxidase  
will normally be added in a concentration of 0.01-100 mg enzyme  
protein per liter, preferably in a concentration of 0.1-50 mg  
enzyme protein per liter, more preferably in a concentration of  
10 0.2-10 mg enzyme protein per liter.

In a preferred embodiment the haloperoxidase is derivable from  
*Curvularia* sp., in particular *C. verruculosa* and *C. inaequalis*.

#### Hydrogen Peroxide Sources

15 According to the invention the hydrogen peroxide needed for  
the reaction with the haloperoxidase may be achieved in many  
different ways: It may be hydrogen peroxide or a hydrogen  
peroxide precursor, such as, e.g., percarbonate or perborate, or  
a peroxy-carboxylic acid or a salt thereof, or it may be a  
20 hydrogen peroxide generating enzyme system, such as, e.g., an  
oxidase and its substrate. Useful oxidases may be, e.g., a  
glucose oxidase, a glycerol oxidase or an amino acid oxidase. An  
example of an amino acid oxidase is given in WO 94/25574.

It may be advantageous to use enzymatically generated  
25 hydrogen peroxide, since this source results in a relatively  
low concentration of hydrogen peroxide under the biologically  
relevant conditions. Low concentrations of hydrogen peroxide  
result in an increase in the rate of haloperoxidase-catalysed  
reaction.

30 According to the invention the hydrogen peroxide source  
needed for the reaction with the haloperoxidase may be added in a  
concentration corresponding to a hydrogen peroxide concentration  
in the range of from 0.01-500 mM, preferably in the range of from  
0.1-100 mM.



The invention also relates to the hygiene products having incorporated a haloperoxidase and a hydrogen peroxide source e.g. in the absorbing material.

## 5 METHODS AND MATERIALS

### Materials:

#### Enzymes:

Recombinant haloperoxidase derived from *Curvularia verruculosa*  
10 CBS 147.63 (rHP) described in WO 97/04102 (Novo Nordisk)

Recombinant peroxidase derived from *Coprinus cinereus* (rCIP)  
(available from Novo Nordisk).

Urease Type III from Jack Beans (Sigma No. U 1500)

#### 15 Artificial Urine A

Urea (300 mM), calcium sulphate (2 mM), magnesium sulphate  
(3.5 mM), potassium chloride (60 mM) and sodium chloride (130  
mM).

#### 20 Artificial Urine B:

Urea (300 mM), sodium chloride (130 mM), potassium chloride  
(60 mM), magnesium sulphate (3 mM), calcium sulphate (2.5 mM),  
Triton X-100 (1g/l). The artificial urine is made in 10 mM  
phosphate buffer and adjusted to pH 6.0

#### 25 Artificial Urine C:

Made as Artificial Urine B only adding also some amino acids  
commonly found in human urine: Lysine (0.5 mM), Glycine (2 mM),  
Alanine (0.5 mM) and Serine (0.5 mM).

#### 30 Micro-organisms:

*Escherichia coli* (DSM 1576)

*Enterococcus faecalis* (DSM 2570)

*Proteus mirabilis* (DSM 788)

#### 35 Superabsorbent:

In the examples below the superabsorbent material used was a

granular crosslinked sodium polyacrylate polymer obtained from SCA Mölnlycke, Sweden (Batch No. 227131).

Equipment:

5 Malthus Flexi M2060 (Malthus Instrument Limited)

**Methods**

Determination of POXU

One POXU is defined as the amount of enzyme which catalyse  
10 the conversion of 1  $\mu$ mol hydrogen peroxide per minute. The activity is measured as oxidation of 2,2'-azinobis [3-ethylbenzothiazoline-6-sulfonate] (ABTS), by monitoring the absorbance at 418 nm at the following conditions: pH 7.0, 30°C, 0.88 mM hydrogen peroxidase, 1.67 mM ABTS and 60 s reaction  
15 time.

Malthus-method

The Malthus-method is based on the methods described in Johnston and Jones, (1995), Journal of Microbiological Methods  
20 21, p. 15-26 and Johansen et al. (1995), Journal of Applied Bacteriology 78, p. 297-303.

Determination of haloperoxidase activity

Color reagent:

25 2.98 g potassium bromide is dissolved in a mixture of 2 ml 0.2 % Phenol Red in 96 % EtOH and 48 ml 0.3 M TRIS buffer pH 7.0

Vanadate solution:

18.4 mg sodium orthovanadate is dissolved in 10 ml de-  
30 ionized water.

Hydrogen peroxide solution:

0.1 ml 30 % hydrogen peroxide is added to 9.9 ml de-ionized water.

When performing the assay, the enzyme sample is pre-  
35 incubated with an amount of the Vanadate solution for a specified period of time and then specified amounts of hydrogen

peroxide and the Color Reagent is added and the activity is monitored by measuring the absorbance at 595 nm (the color changes from red to bluish violet).

5 Determination of smell:

Evaluation of smell was performed by a test panel of three trained persons.

**EXAMPLES**

10

**Example 1**

**Antibacterial activity of peroxidase against *Escherichia coli*, *Enterococcus faecalis* and *Proteus mirabilis* attached to pulp material**

15 The anti-microbial activity of *Cuicularia verruculosa* haloperoxidase was evaluated in artificial urine A against *Escherichia coli* (DSM 1576), *Enterococcus faecalis* (DSM 2570) and *Proteus mirabilis* (DSM 788) adhering to pulp material.

20 The anti-microbial activity was determined as reduction in living bacterial cells (bactericidal activity) by use of impedance measurements (Malthus).

The detection times measured by the Malthus instrument were converted to cfu/ml by a calibration curve. Either direct or Indirect Malthus measurements were used when enumerating total survival cells (Malthus Flexi M2060, Malthus Instrument Limited). By the direct measurements, the cell metabolism was determined by conductance measurements in the growth substrate.

25 By the indirect measurements, 3 ml of growth medium was transferred to the outer chamber of the indirect Malthus cells, and 0.5 ml of sterile KOH (0.1 M) was transferred to the inner chamber. The cell suspensions were after enzyme treatment transferred to the outer chamber of the Malthus cell. As cells are growing in the outer chamber they produce CO<sub>2</sub> which will dissolve in the KOH in the inner chamber and thereby change the conductance of the KOH. The amount of CO<sub>2</sub> formed by the respiring cells surviving the enzyme treatment was used for estimating the number of viable cells. When the conductance

30

35

change is measurable by the Malthus, a detection time (dt) will be recorded. The dt's were converted to colony counts by use of a calibration curve relating cfu/ml to dt.

The strains were grown in Brain Heart Infusion (BHI) (Oxoid CM 225) until stationary growth phase (30°C, 20 hours), diluted in peptone water and inoculated to chemo-thermo-mechanical-pulp CTMP at the final cell concentration of approximately  $10^4$  cfu/0.01g CTMP. The CTMP was inoculated with either mono-cultures or a mixed culture of the three strains.

The anti-microbial activity of the haloperoxidase (was determined at 35°C for 30 minutes, by adding the haloperoxidase to the bacterial cells adhering to the CTMP, together with hydrogen peroxide (0.5 mM) and artificial urine. The number of living cells was determined by transfer of the CTMP to Malthus cells.

The activity of the haloperoxidase (0-2 mg enzyme protein/1 urine) was evaluated in artificial urine without electron-donor, thus the enzyme activity was initiated by the  $\text{Cl}^-$  in the urine.

The haloperoxidase caused a total kill of the three test organisms; *E. faecalis*, *E. coli* and *P. mirabilis*.

Furthermore the anti-microbial activity of the haloperoxidase was unchanged in artificial urine compared to a buffer system (pH 6). A total kill of the mixed culture was found at haloperoxidase concentrations above 1.5 mg/l and a hydrogen peroxide concentration above 0.75 mM (Figure 1).

## Example 2

**Difference between the use of a peroxidase with thiocyanate or iodide as electron donor and the haloperoxidase system.**

The antibacterial activity of the haloperoxidase system with chloride from artificial urine A as electron donor (Example 1) and hydrogen peroxide as electron acceptor, was compared with the antibacterial activity of a peroxidase system using either thiocyanate (20 mM) or iodide (1 mM) as electron donor and hydrogen peroxide (0.5 mM) as electron acceptor.

*Coprinus* peroxidase has antibacterial activity by oxidation of either iodide or thiocyanate. The antibacterial activity was measured by Malthus as described in Example 1, the activity was determined against both planktonic cells suspended in  
5 artificial urine and cells on CTMP material. *Coprinus* peroxidase (Novo Nordisk A/S) (rCIP), with an antibacterial activity comparable to the well-known lactoperoxidase system, was used in concentrations from 0 to 4 POXU/ml.

The rCIP/thiocyanate system was inhibited by the high salt  
10 concentration in the artificial urine whereas the rCIP/iodide systems was found active in artificial urine (Figure 2).

However, both thiocyanate and iodide based systems were significantly inhibited if CTMP was present in the artificial urine (Figure 3) due to interactions between the pulp material  
15 and thiocyanate and iodide, respectively, thus these systems have increased activity in the CTMP material used in nappies.

The haloperoxidase system was not inhibited by the CTMP material (Figure 1 and 3) as a total kill of the bacteria on CTMP was measured.

### Example 3

#### Inhibition of malodour formation by inhibiting Urease using a haloperoxidase

Experiments were performed using 10 ml Artificial Urine B.  
25 Initially, hydrogen peroxide was added to a final concentration of 1 mM and then recombinant *Curvularia verruculosa* haloperoxidase was added to the desired concentration.

The experiments were initiated by addition of Urease. Samples were incubated on a shaking water bath at 25 °C in  
30 closed vessels.

Urease activity in the samples was evaluated at given time intervals by monitoring pH (using a Radiometer PHM 85 precision pH Meter) and production of ammonia monitored by the development of the characteristic malodour.

**Results:**

Table 1

Haloperoxidase (mg/l)	Urease (U/ml)	pH at 15 min	Smell at 15 min	pH at 45 min
0	10	8.5	Strong	8.8
0.1	10	8.4	Strong	8.7
0.5	10	6.2	None	6.2
1.0	10	6.0	None	6.0

- 5 This example clearly illustrates that the haloperoxidase/H<sub>2</sub>O<sub>2</sub> system is capable, in a dose dependent manner, of completely inactivating Urease and thereby prevent the development of malodour from the samples.

10 **Example 4**

**Immobilization of haloperoxidase on a superabsorbent polymer:**

- 2 ml of a solution of recombinant *Cuvularia verrucolosa* haloperoxidase (0.375 mg/ml) was added drop-wise to 20 g vigorously stirred superabsorbent polymer in a glass beaker.  
15 Then, water was removed by drying the material overnight in a vacuum oven at 25 °C.

The activity of the immobilized haloperoxidase was monitored by adding 80 µl Vanadate solution to 100 mg of the superabsorber followed by vigorous mixing on a Whirl mixer.

- 20 One minute later, 800 µl color solution and 80 µl hydrogen peroxide solution was added and the sample was mixed again. In a blank sample of the neat superabsorbent polymer the color remained bright yellow while the color quickly changed to dark purple in the sample containing immobilized haloperoxidase.

- 25 The immobilized haloperoxidase preparation was split into two equivalent samples and one was stored at 5 °C while the other was stored at room temperature.

- After 10 days the activities of the two samples were assayed as above and no visual difference was observed neither between  
30 the samples not to the sample assayed immediately after

immobilization.

The activity was also monitored using a slightly modified activity assay in which the Color Reagent was made using Artificial Urine C in stead of 0.3 MTRIS buffer pH 7. In this case, the Color Reagent has a bright yellow color but the same dark purple color was developed when added to the immobilized haloperoxidase sample when performing the assay.

This example shows that haloperoxidase can be efficiently immobilized on the superabsorbent polymer used in hygienic products. Furthermore, the immobilized enzyme has activity also in the presence of Artificial Urine and exhibits high stability even at room temperature.

#### **Example 5**

##### **Inhibiting maldour formation using immobilized haloperoxidase.**

The ability of immobilized haloperoxidase to inactivate Urease and thereby inhibit malodour formation was monitored by using 100 mg superabsorbent either neat or with immobilized haloperoxidase (as prepared in Example 4).

The samples were either mixed thoroughly with 5 mg sodium perborate trihydrate (Merck, Art. 1.06560.) and then added 100 µl Artificial Urine C or the samples were added 1000 µl Artificial Urine C mixed with 125 µl 0.3 % hydrogen peroxide.

Following vigorously mixing on a Whirl mixer 500 µl a solution of Urease (10 U/ml) was immediately added followed by mixing again.

The samples were incubated on a shaking water bath at 25 °C in closed vessels and Urease activity was monitored at given time intervals by monitoring pH in the samples by contacting a small part of the sample with pH indicator strips (Merck Neutralit pH 5-10; Art. 1-09533.) and by evaluating production of ammonia by monitoring the characteristic malodour.

Results:

Table 2

Haloperoxi- dase added to SAP	Perbora- te addition	H <sub>2</sub> O <sub>2</sub> addition	After 5 min		After 30 min	
			pH	Smell	pH	Smell
-	-	-	7.5	faint	9	strong
-	+	-	6.5	faint	9	medium
+	-	-	8	faint	9	strong
+	+	-	6	none	6	none
+	-	+	6	none	6	none

5

This example clearly demonstrates that haloperoxidase immobilized on a superabsorbent polymer in combination with hydrogen peroxide is capable of completely preventing the formation of malodour which is normally the result of Urease action on urine.

10

The example also demonstrates that hydrogen peroxide can be conveniently added to the system in the form of the solid sodium perborate.

15



## PATENT CLAIMS

1. Use of a haloperoxidase in combination with a hydrogen peroxide source for reducing the malodour in hygiene products.

5

2. The use according to claim 1, wherein the haloperoxidase is obtainable from fungi, from bacteria, or from algae.

3. The use according to claim 2, wherein the haloperoxidase is obtainable from a fungus selected from the group consisting of *Caldariomyces*, *Alternaria*, *Curvularia*, *Drechslera*, *Ulocladium* and *Botrytis*.

4. The composition according to claim 3, wherein the haloperoxidase is obtainable from *Curvularia verruculosa*, such as *Curvularia verruculosa* CBS 147.63, or the haloperoxidase is immunologically cross-reactive with the haloperoxidase obtainable from *Curvularia verruculosa* CBS 147.63.

5. The use according to claim 2, wherein the haloperoxidase is obtainable from a bacterium selected from the group consisting of *Pseudomonas* and *Streptomyces*.

6. The use according to any of claims 1 to 5, wherein the hydrogen peroxide source is hydrogen peroxide, or a hydrogen peroxide precursor.

7. The use according to any of claims 1 to 6, wherein the hygiene product is a diaper or an adult incontinence product or a pair of training pants or a feminine napkin or a tampon.

8. A hygiene product having a haloperoxidase and a hydrogen peroxide source incorporated.

9. The product according to claim 8, wherein the haloperoxidase and the hydrogen peroxide source are incorporated in the

absorbing material.

10. The product according to claims 8 and 9 being a diaper or an adult incontinence product or a pair of training pants or a  
5 feminine napkin or a tampon.

1/3




Figure 1

2/3




Figure 2

3/3




Figure 3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00352

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61L 15/38, A61L 15/46

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61L, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 9504135 A1 (EXOHEMIS, INC.), 9 February 1995 (09.02.95), page 9, line 4 - line 14, abstract, claims	1-10
Y	WO 9702846 A1 (SCA MÖLNLYCKE AB), 30 January 1997 (30.01.97), abstract	1-10
A	WO 9527046 A2 (UNILEVER N.V.), 12 October 1995 (12.10.95), abstract, claims	1-10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

25 November 1998

Date of mailing of the international search report

26-11-1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Jack Hedlund

Telephone No. +46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

03/11/98

International application No.

PCT/DK 98/00352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9504135 A1	09/02/95	AU 679777 B	10/07/97
		AU 7477294 A	28/02/95
		CA 2167525 A	09/02/95
		CN 1128044 A	31/07/96
		EP 0713527 A	29/05/96
		JP 9503752 T	15/04/97
		US 5389369 A	14/02/95
		US 5451402 A	19/09/95
		US 5510104 A	23/04/96
		US 5756090 A	26/05/98
WO 9702846 A1	30/01/97	AU 6374496 A	10/02/97
		EP 0871503 A	21/10/98
		GB 2303305 A	19/02/97
		GB 9614473 D	00/00/00
		PL 324454 A	25/05/98
		SE 9502588 A	14/01/97
WO 9527046 A2	12/10/95	AU 2085995 A	23/10/95
		AU 2215495 A	23/10/95
		BR 9507226 A	09/09/97
		CA 2182966 A	12/10/95
		CN 1146782 A	02/04/97
		CZ 9602850 A	15/10/97
		EP 0753055 A	15/01/97
		HU 74967 A	28/03/97
		HU 9602673 D	00/00/00
		JP 9511396 T	18/11/97
		NL 9401048 A	01/11/95
		PL 316571 A	20/01/97
		SK 123096 A	04/06/97
		WO 9527009 A	12/10/95

**THIS PAGE BLANK (USPTO)**